Current through Register Vol. 56, No. 24, December 18, 2024
(a) The following
classes of prescription drugs or conditions are not covered under the Medicaid
or NJ FamilyCare fee-for-service programs. For beneficiaries in the Medically
Needy component of the New Jersey Care... Special Medicaid Programs,
pharmaceutical services are not available to the aged, blind, nor the disabled
who are residing in a long-term care facility (except a nursing facility) or in
the community. For information on how to identify a covered person, see
N.J.A.C. 10:49, Administration.
1. Prescriptions which are not for medically
accepted indications as defined in Section 1927(k)(6) of the Social Security
Act;
2. Antiobesics and
anorexiants, with the exception of lipase inhibitors, when used in treatment of
obesity (see
N.J.A.C. 10:51-1.14, Prior authorization);
coverage of lipase inhibitors shall be limited to obese individuals with a Body
Mass Index (BMI) equal to or greater than 27 kg/m2 and less than 30 kg/m2 with
co-morbidities of hypertension, diabetes or dyslipidemia; and obese individuals
with a BMI equal to or greater than 30 kg/m2 without comorbidities;
3. Drug products for which adequate and
accurate information is not readily available, such as, but not limited to,
product literature, package inserts and price catalogues;
4. Experimental drugs;
i. Exception: Drugs available only for
treatment through an Investigational New Drug (IND) application shall be prior
authorized;
5.
Medication furnished by a prescriber or an employee of a prescriber;
6. Medication prescribed for hospital
inpatients;
7. Non-legend drugs
other than antacids; contraceptive devices and contraceptive supplies; diabetic
testing materials; over-the-counter (OTC) family planning supplies; inhalation
devices (pharmaceutical); insulin; and insulin needles and/or syringes;
i. Exception: Non-legend drugs described in
N.J.A.C. 10:51-1.11, for beneficiaries
under 21 years of age.
8. Prescriptions written and/or dispensed
with nonspecific directions;
9.
Food supplements, milk modifiers, infant formulas, therapeutic diets, special
liquid or powdered diets used in the treatment of obesity;
i. Exception: Enteral nutritional products
and electrolyte replacement supplements;
10. Methadone in any form (tablets, capsules,
liquid, injectables, or powder) when used for drug detoxification or addiction
maintenance;
11. Drug products for
which final orders have been published by the Food and Drug Administration,
withdrawing the approval of their new drug application (NDA);
12. Drugs or drug products not approved by
the Food and Drug Administration, when such approval is required by Federal law
and/or regulation;
13. Radiopaque
contrast materials (for example, Telepaque);
14. Drug Efficacy Study Implementation (DESI)
drugs and identical, similar and related drugs (see
N.J.A.C. 10:51-1.21);
15. Drugs not covered by rebate agreements as
defined in Section 4401 of OBRA '90 and Section 1927(a) of the Social Security
Act (see N.J.A.C. 10:51-1.22);
16. Erectile dysfunction drugs for
individuals who are registered on New Jersey's Sex Offender Registry;
17. Any bundled drug service (see
N.J.A.C. 10:51-1.23);
18. Preventive vaccines, biologicals, and
therapeutic drugs distributed to hospital clinics and/or community health
centers by the New Jersey Department of Health; and
19. Drugs provided primarily for the
treatment of infertility or which may be used to treat other conditions related
to infertility, including fertility preparations and gonadotropic (follicle
stimulating and luteinizing) hormones.
i. When
a drug is provided that is ordinarily considered an infertility drug, but is
provided for conditions unrelated to infertility, the claim must be sent with
supporting documentation for medical review and approval of payment to the
Division of Medical Assistance and Health Services, Office of Medical Affairs
and Provider Relations, PO Box 712, (Mail Code #14), Trenton, New Jersey
08625-0712.
(b) Otherwise reimbursable products shall be
excluded from payment, under the following condition(s):
1. Products whose costs are found to be in
excess of defined costs outlined in
N.J.A.C. 10:51-1.5, Basis of
payment;
2. Drug products in dosage
forms whose labeling, prescription or promotional material indicate the primary
use is cosmetic in nature; for example, hair restoration;
3. Drug products available in unit-dose
and/or unit-of-use packaging and dispensed to residents in a boarding home,
residential care setting, alternative family care (AFC) home or other community
type setting. Other community type settings shall not include certain assisted
living settings, including assisted living residences (ALRs) or comprehensive
personal care homes (CPCHs) licensed by the Department of Health and Senior
Services.
i. Drug products commercially
available only as a unit-dose packaged product are covered in all settings when
not otherwise marketed as a chemically equivalent product. The potency of the
equivalent products may or may not equal the potency of the unit-dose-packaged
product.
4.
Prescriptions refilled too soon, as described in N.J.A.C. 10:51-1.19(a)5; and
5. Drug products
denied payment based on point-of-sale (POS) and prospective drug utilization
review (PDUR) standards adopted by the Medicaid or NJ FamilyCare program. (see
N.J.A.C. 10:51-1.26)
(c) Reimbursement shall not be
made for any claim submitted by a provider which involves a beneficiary
restricted to another pharmacy, except for an emergency situation (see N.J.A.C.
10:49, Administration).